Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2.

Abstract

BACKGROUND:

Baricitinib, an oral selective JAK1/JAK2 inhibitor, is approved for the treatment of adults with severe alopecia areata (AA).

OBJECTIVE:

To evaluate differences in response up to week 52 among subgroups based on the baseline severity of AA assessed with the Severity of Alopecia Tool (SALT) score.

METHODS:

Data were pooled from BRAVE-AA1 and BRAVE-AA2, two randomized, placebo-controlled, phase 3 trials, which enrolled adults with a SALT score ≥ 50. Patients were subdivided by the degree of AA severity at baseline.

RESULTS:

Among the 855 patients treated with baricitinib 2 mg and 4 mg, improvements in scalp hair growth continued through to week 52. A superior response was observed in patients with a SALT score of 50-94 versus a score of 95-100. Patients on baricitinib 4 mg had a faster and higher response rate compared to baricitinib 2 mg.

CONCLUSION:

Across all degrees of severity for baricitinib 2 mg and 4 mg doses, the proportion of patients responding was yet to plateau up to week 52. Response to treatment was longer for patients with a baseline SALT score 95-100. Further studies are needed to analyze other parameters that may impact observed response rates.

• Authors: Susan Taylor, Neil J Korman, Tsen-Fang Tsai, Yutaka Shimomura, Meghan Feely, Yves Dutronc, Wen-Shuo Wu, Najwa Somani, Antonella Tosti
• Journal: Dermatology and therapy (Dermatol Ther (Heidelb)) Vol. 13 Issue 12 Pg. 3181-3191 (Dec 2023) ISSN: 2193-8210 [Print] Switzerland
• PMID: 37740856 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s).